Rapid Micro Biosystems to Participate in the Stifel 2025 Healthcare Conference




Rapid Micro Biosystems to Participate in the Stifel 2025 Healthcare Conference

LEXINGTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2025 Healthcare Conference in New York, NY.

Company management is scheduled to participate in a 30-minute question-and-answer session with the host analyst on Tuesday, November 11, 2025, at 11:20 a.m. ET. A live webcast will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.

CONTACT: Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
mbeaulieu@rapidmicrobio.com

Media Contact:
media@rapidmicrobio.com

Corbus Pharmaceuticals Announces Proposed Public Offering




Corbus Pharmaceuticals Announces Proposed Public Offering

NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. All of the securities in the offering are to be sold by Corbus. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Corbus intends to use the net proceeds of the proposed underwritten offering to fund the clinical development of its pipeline and for working capital and other general corporate purposes.

Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering. Corbus intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and became effective on March 20, 2024. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering will be made only by means of a prospectus, copies of which may be obtained, when available, at the SEC’s website at www.sec.gov, or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts.

Forward-Looking Statements

Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about Corbus’ expectations regarding the completion, timing and size of its public offering and the anticipated use of proceeds therefrom. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties associated with Corbus’ business and finances in general, including the risks and uncertainties in the section captioned “Risk Factors” in the preliminary prospectus supplement related to the public offering that will be filed with the SEC and the Company’s most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q. There can be no assurances that we will be able to complete the proposed offering on the anticipated terms, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corbus undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Corbus Pharmaceuticals Contacts: 

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors




DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

Châtillon, France, October 30, 2025

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company’s shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company’s Board comprises ten directors.

“We are pleased to welcome Philina Lee as a new independent director to the Board,” said Michel de Rosen, Chairman of the Board. “Philina’s extensive experience building successful biopharmaceutical organizations and commercializing pharmaceutical products will add tremendous value as the Company moves closer to potential commercialization.”

Dr. Lee joins DBV following a distinguished tenure at Blueprint Medicines where she progressed through increasingly senior roles, culminating in her leadership of the company’s commercial organization as Chief Commercial Officer, overseeing the successful launch and growth of AYVAKIT®. She previously was on the Board of Directors at Fusion Pharmaceuticals, where she served on both the Nomination and Governance Committee and the Research and Development Committee.

“I am honored to join DBV’s Board at such a pivotal time for the Company, as it continues to advance VIASKIN® Peanut for children and toddlers with peanut allergy,” said Dr. Lee. “I look forward to serving on the Compensation Committee and contributing to DBV’s growth and success.”

About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

VIASKIN is a registered trademark of DBV Technologies.

Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com

Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com

Attachment

• PDF Version

Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025




Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025

SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present a trial-in-progress poster for the Phase 3 OPERA-02 trial at the 2025 San Antonio Breast Cancer Symposium (SABCS 2025) taking place December 9-12, 2025 in San Antonio, TX. The trial is evaluating palazestrant in combination with ribociclib in frontline estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

Poster Presentation Details
Title: OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer
Abstract Number: 264
Presentation Number: PS5-12-18
Date/Time: Friday, December 12, 2025 from 12:30pm–2:00pm CT / 1:30pm–3:00pm ET

Additional information can be found on the SABCS website. A copy of the poster will be made available on the Publications page of Olema’s website in alignment with the SABCS 2025 embargo policy.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

About Palazestrant (OP-1250)
Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and has demonstrated anti-tumor efficacy along with attractive pharmacokinetics and exposure, favorable tolerability, central nervous system penetration, and combinability with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01 and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02. Palazestrant is also being evaluated in multiple Phase 1/2 studies in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

Psychologie Berlin’s Dr. Dirk Stemper Announces New Book: The Vagus Nerve: Why You Don’t Need a Reset – Real Neuromodulation for Exhaustion, Trauma, and Long COVID




Psychologie Berlin’s Dr. Dirk Stemper Announces New Book: The Vagus Nerve: Why You Don’t Need a Reset – Real Neuromodulation for Exhaustion, Trauma, and Long COVID

New book reveals evidence-based approaches for nervous system dysfunction—debunking quick fixes and offering actionable strategies in neuromodulation, biofeedback, and trauma recovery.

Vagus Nerve—Science, Not Myth: Dr. Dirk Stemper Exposes Reset Myths and Offers Research-Based Solutions for Fatigue, Inflammation, and Long COVID

Berlin, Germany, Oct. 30, 2025 (GLOBE NEWSWIRE) —  Chronic fatigue, persistent inflammation, and long COVID symptoms drive millions to search for answers about the vagus nerve every month. Psychologie Berlin, alongside founder Dr. Dirk Stemper, internal medicine specialist and psychotherapist, releases “The Vagus Nerve: Why You Don’t Need a Reset – Real Neuromodulation for Exhaustion, Trauma, and Long COVID”, a new book that delivers science-driven clarity for health professionals and individuals struggling with exhaustion and chronic disease.

Science, Not Myth: Dr. Dirk Stemper’s new book, The Vagus Nerve, delivers evidence-based solutions for exhaustion, trauma, and long COVID—debunking wellness industry reset myths and revealing the real power of gentle neuromodulation.

Five Ws: Core Facts

– Who: Dr. Dirk Stemper, M.D., a German board-certified internal medicine specialist and practicing psychotherapist (20+ years clinical experience).

– What: Launch of an evidence-based book debunking vagus nerve “reset” myths and wellness industry misinformation.

– When: October 2025, global release in hardcover, paperback, audiobook and eBook formats.

– Where: Available worldwide on amazon.com, published by Psychologie Halensee.

– Why: To educate about real causes and solutions for nervous system dysfunction, chronic fatigue, dysautonomia, post-viral syndromes, and the value of neuromodulation.

 Key Takeaways

– Quick fixes and “vagus nerve resets” lack scientific support; Dr. Stemper details the real anatomy, function, and therapeutic interventions.

– Exhaustion, CPTSD, neurodiversity, and inflammation are explained as biopsychosocial patterns, not personal defects.

– Modern, gentle neuromodulation (transcutaneous stimulation, HRV biofeedback) emerges as a promising clinical approach, validated by peer-reviewed research.

– Readers gain actionable strategies without relying on pseudoscience or pricey gadgets.

 Expert Quote

“This book clarifies how nervous system support must be rooted in evidence, not hype. My goal is for patients and caregivers to see beyond the noise—toward compassionate, research-based care,” said Dr. Dirk Stemper.

FAQ

Q: Who should read this book? 

A: Patients, and caregivers dealing with chronic fatigue, inflammation, long COVID, trauma, or interest in biofeedback and neuromodulation therapies.

Q: What makes this book different from wellness guides? 

A: It dispels reset myths, avoids self-optimization culture, and provides clinically reviewed research and practical steps.

Q: Is the vagus nerve important for long COVID or CPTSD? 

A: Yes. The book describes how vagus nerve modulation influences inflammation, autonomic balance, and trauma recovery.

Q: What methods does Dr. Stemper endorse? 

A: Non-invasive, evidence-based neuromodulation: electrical, magnetic, or sensory stimulation and HRV biofeedback.

 Author Boilerplate

Dr. Dirk Stemper, is a board-certified internist and practicing psychotherapist specializing in trauma recovery and neurodiversity. With over two decades of clinical and research experience, he advocates for scientific rigor in integrative medicine.

Dr. Dirk Stemper, internal medicine specialist and psychotherapist, author of The Vagus Nerve—Science, Not Myth: Why You Don’t Need a Reset—dedicated to evidence-based solutions for exhaustion, trauma, and long COVID.

About Psychologie Berlin

Psychologie Berlin is a Berlin-based private practice focused on integrative mental health, offering evidence-based psychotherapy and medical consultation with specialization in trauma recovery, neurodiversity, and nervous system regulation. Bridging clinical psychology and internal medicine, the practice supports individuals facing chronic fatigue, post-viral conditions, and stress-related disorders with a biopsychosocial approach. Dr. Dirk Stemper is a doctor, psychotherapist, and coach based in Berlin. At Psychologie Berlin, he regularly publishes on health and societal issues (most recently with Orientations Press, 2025). 

Press inquiries

Psychologie Berlin
https://www.praxis-psychologie-berlin.de
Dr. Dirk Stemper
info@praxis-psychologie-berlin.de
‭+49 179 5911328‬
Kalckreuthstr. 16
10777 Berlin
c./o. AVATARAS Institut
Germany

Psychologie Berlin’s Dr. Dirk Stemper Announces New Book: The Vagus Nerve: Why You Don’t Need a Reset – Real Neuromodulation for Exhaustion, Trauma, and Long COVID




Psychologie Berlin’s Dr. Dirk Stemper Announces New Book: The Vagus Nerve: Why You Don’t Need a Reset – Real Neuromodulation for Exhaustion, Trauma, and Long COVID

New book reveals evidence-based approaches for nervous system dysfunction—debunking quick fixes and offering actionable strategies in neuromodulation, biofeedback, and trauma recovery.

Vagus Nerve—Science, Not Myth: Dr. Dirk Stemper Exposes Reset Myths and Offers Research-Based Solutions for Fatigue, Inflammation, and Long COVID

Berlin, Germany, Oct. 30, 2025 (GLOBE NEWSWIRE) —  Chronic fatigue, persistent inflammation, and long COVID symptoms drive millions to search for answers about the vagus nerve every month. Psychologie Berlin, alongside founder Dr. Dirk Stemper, internal medicine specialist and psychotherapist, releases “The Vagus Nerve: Why You Don’t Need a Reset – Real Neuromodulation for Exhaustion, Trauma, and Long COVID”, a new book that delivers science-driven clarity for health professionals and individuals struggling with exhaustion and chronic disease.

Science, Not Myth: Dr. Dirk Stemper’s new book, The Vagus Nerve, delivers evidence-based solutions for exhaustion, trauma, and long COVID—debunking wellness industry reset myths and revealing the real power of gentle neuromodulation.

Five Ws: Core Facts

– Who: Dr. Dirk Stemper, M.D., a German board-certified internal medicine specialist and practicing psychotherapist (20+ years clinical experience).

– What: Launch of an evidence-based book debunking vagus nerve “reset” myths and wellness industry misinformation.

– When: October 2025, global release in hardcover, paperback, audiobook and eBook formats.

– Where: Available worldwide on amazon.com, published by Psychologie Halensee.

– Why: To educate about real causes and solutions for nervous system dysfunction, chronic fatigue, dysautonomia, post-viral syndromes, and the value of neuromodulation.

 Key Takeaways

– Quick fixes and “vagus nerve resets” lack scientific support; Dr. Stemper details the real anatomy, function, and therapeutic interventions.

– Exhaustion, CPTSD, neurodiversity, and inflammation are explained as biopsychosocial patterns, not personal defects.

– Modern, gentle neuromodulation (transcutaneous stimulation, HRV biofeedback) emerges as a promising clinical approach, validated by peer-reviewed research.

– Readers gain actionable strategies without relying on pseudoscience or pricey gadgets.

 Expert Quote

“This book clarifies how nervous system support must be rooted in evidence, not hype. My goal is for patients and caregivers to see beyond the noise—toward compassionate, research-based care,” said Dr. Dirk Stemper.

FAQ

Q: Who should read this book? 

A: Patients, and caregivers dealing with chronic fatigue, inflammation, long COVID, trauma, or interest in biofeedback and neuromodulation therapies.

Q: What makes this book different from wellness guides? 

A: It dispels reset myths, avoids self-optimization culture, and provides clinically reviewed research and practical steps.

Q: Is the vagus nerve important for long COVID or CPTSD? 

A: Yes. The book describes how vagus nerve modulation influences inflammation, autonomic balance, and trauma recovery.

Q: What methods does Dr. Stemper endorse? 

A: Non-invasive, evidence-based neuromodulation: electrical, magnetic, or sensory stimulation and HRV biofeedback.

 Author Boilerplate

Dr. Dirk Stemper, is a board-certified internist and practicing psychotherapist specializing in trauma recovery and neurodiversity. With over two decades of clinical and research experience, he advocates for scientific rigor in integrative medicine.

Dr. Dirk Stemper, internal medicine specialist and psychotherapist, author of The Vagus Nerve—Science, Not Myth: Why You Don’t Need a Reset—dedicated to evidence-based solutions for exhaustion, trauma, and long COVID.

About Psychologie Berlin

Psychologie Berlin is a Berlin-based private practice focused on integrative mental health, offering evidence-based psychotherapy and medical consultation with specialization in trauma recovery, neurodiversity, and nervous system regulation. Bridging clinical psychology and internal medicine, the practice supports individuals facing chronic fatigue, post-viral conditions, and stress-related disorders with a biopsychosocial approach. Dr. Dirk Stemper is a doctor, psychotherapist, and coach based in Berlin. At Psychologie Berlin, he regularly publishes on health and societal issues (most recently with Orientations Press, 2025). 

Press inquiries

Psychologie Berlin
https://www.praxis-psychologie-berlin.de
Dr. Dirk Stemper
info@praxis-psychologie-berlin.de
‭+49 179 5911328‬
Kalckreuthstr. 16
10777 Berlin
c./o. AVATARAS Institut
Germany

Wounded Warriors Family Support, AMVET Power Announce Strategic Partnership to Empower Veterans




Wounded Warriors Family Support, AMVET Power Announce Strategic Partnership to Empower Veterans

OMAHA, Neb., Oct. 30, 2025 (GLOBE NEWSWIRE) — Wounded Warriors Family Support and AMVET Power have announced a new charity partnership dedicated to enhancing support for our nation’s wounded veterans, their families and caregivers. This collaboration unites two organizations with a shared mission that aims to strengthen outreach, expand veteran training and employment and raise awareness for critical veteran services.

“This partnership establishes a powerful framework for cooperation,” Wounded Warriors Family Support President and CEO Kate McCauley said. “A key component of this alliance is the referral of our newly accredited Veterans Welding Training Program graduates to AMVET Power for employment placement to directly addresses the need for meaningful career paths for those who have served.”

Upon successful completion of the Veterans Welding Training Program, AMVET Power will provide dedicated assistance to WWFS graduates to secure long-term employment opportunities. This career placement support will help veterans find roles in their home states or assist with relocation, if desired, to ensure a stable transition into the civilian workforce.

“Partnership and collaboration are among our values,” AMVET Power Vice President of Business Development Donovan Kohls said. “Wounded Warriors Family Support is a perfect veteran service organization partner to help us deliver training and job placement. This mutual brand recognition will increase visibility for the services each organization provides.”

To amplify their shared goals, both organizations will engage in promotional collaboration. Wounded Warriors Family Support will feature AMVET Power as a charity partner across its website, marketing materials and media outreach. In turn, AMVET Power will display the WWFS name and logo to highlight the partnership to demonstrate a unified front in its commitment to veteran families.

About Wounded Warriors Family Support
Wounded Warriors Family Support is an independent nonprofit organization whose mission is to provide support to the families of those who have been wounded, injured, or killed during combat operations. This organization is run by combat veterans for combat veterans. Rated a four-star charity by Charity Navigator, Wounded Warriors Family Support aids veterans and their families in healing the wounds that medicine cannot. More information is available at wwfs.org.

About AMVET Power
AMVET Power helps veterans turn their service into high-impact careers in clean energy, defense, construction and more. AMVET Power offers a resume builder, role-aligned training and direct placement into employer pipelines. Its mission is supported by the Service2Success program, which automatically translates a veteran’s MOS/MOC codes into civilian resumes and identifies up-skilling pathways. Additional information is available at amvetpower.com.

Media Contact:
Kevin Schuster, PR Counsel                        
Cell: 402.917.6001                                
Email: kschuster@lukaspartners.com

Good Samaritan President and CEO Honoured Among Canada’s Most Powerful Women




Good Samaritan President and CEO Honoured Among Canada’s Most Powerful Women

EDMONTON, Alberta, Oct. 30, 2025 (GLOBE NEWSWIRE) — The Good Samaritan Society and Good Samaritan Canada (Good Samaritan) are proud to announce that Dr. Katherine Chubbs, President and CEO, has been named one of Canada’s Most Powerful Women: Top 100 Award Winners by the Women’s Executive Network (WXN).

This national recognition celebrates outstanding women across Canada who demonstrate bold leadership, vision, and impact within their industries and communities. The 2025 theme, Rise Boldly, honours women who are transforming challenge into opportunity and courage into legacy.

“Dr. Chubbs embodies what it means to rise boldly,” said Marlene Raasok, Board Chair, Good Samaritan. “Her compassionate leadership and unwavering commitment to person-centered care have strengthened Good Samaritan’s mission and inspired our teams to make a difference every day. This recognition is a reflection of her character, dedication, and the positive change she continues to drive in the continuing care sector.”

Since joining Good Samaritan in 2020, Dr. Chubbs has led transformative initiatives to enhance quality of living, empower employees, and advance equity, diversity, inclusion and Reconciliation across all levels of the organization. Under her leadership, Good Samaritan continues to build sustainable, faith-based communities that foster belonging, dignity, and purpose for seniors and individuals with complex needs throughout Alberta and British Columbia.

“I am deeply honoured to be recognized alongside so many extraordinary leaders,” said Dr. Katherine Chubbs. “To rise boldly means to lead with courage and compassion, to break barriers with integrity, and to lift others along the way. This award reflects not just my journey, but the collective strength of our Good Samaritan family and our shared commitment to serve with excellence.”

The 2025 Canada’s Most Powerful Women: Top 100 Award Winners were announced by WXN on October 30, 2025. Winners will be celebrated at the Top 100 Awards Gala on November 27, 2025, at the Fairmont Royal York in Toronto.

A full list of award recipients is available at https://wxnetwork.com/page/2025Top100AwardWinners.

About Good Samaritan

As the largest faith-based, not-for-profit provider of senior care and programs in Western Canada, The Good Samaritan Society and Good Samaritan Canada are committed to creating safe, inclusive, and compassionate communities where individuals experience caring, belonging, and purpose. With over 76 years of service, Good Samaritan provides continuing care, assisted and supportive living, and specialized health programs guided by the values of Excellence, Inclusion, Healthy Relationships, and Servant Leadership.
Learn more at www.gss.org.

About WXN

The Women’s Executive Network (WXN) celebrates and inspires women leaders across Canada, providing access to networking, mentorship, and learning opportunities to support women in achieving their full potential. Through its annual Canada’s Most Powerful Women: Top 100 Awards, WXN honours outstanding women who are shaping the future of business, government, healthcare, education, and community leadership.
Learn more at www.wxnetwork.com.

For media inquiries, contact:

Paola Gatica
Director, Communications and Board Support
The Good Samaritan Society
Email: pegatica@gss.org
Phone: 780-907-9265

Resuscitec’s CARL® ECPR System Wins the Prix Galien USA 2025 “Best Startup” Award




Resuscitec’s CARL® ECPR System Wins the Prix Galien USA 2025 “Best Startup” Award

Industry’s top honor recognizes Resuscitec’s life-restoring technology redefining outcomes after sudden cardiac arrest

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) — Resuscitec GmbH today announced that its CARL® ECPR system has won the Prix Galien USA 2025 Award in the “Best Startup” category, cementing the technology’s place as a breakthrough in lifesaving care for patients experiencing sudden cardiac arrest. Often called the “Nobel Prize of biopharmaceutical research,” the Prix Galien recognizes innovations that meaningfully improve the human condition.

In the highly challenging group of patients with acute cardiac arrest, the CARL® system takes over heart and lung function after sudden cardiac arrest, providing circulation and gas exchange and starting immediately with a physiologically driven therapy until the patient’s own cardiovascular system can be restored, introducing a new standard in survival and neurological outcomes. The CE-marked platform has been used very successfully in over 750 clinical cases in Europe. In the highly challenging group of patients with acute cardiac arrest, survival rates exceeded 50%, with 80% of survivors having no brain damage, even after being without spontaneous circulation for up to 90 minutes—compared to less than 10% survival with conventional CPR, where brain injury is common.

“We are deeply honored to receive the Prix Galien USA Award,” said Dr. Thomas Lines, Chief Scientific Officer of Resuscitec. “This recognition belongs not only to our team, but also to the innovators and clinical pioneers who came before us, the researchers, physicians, engineers, and first responders whose work paved the way for CARL®. We stand on the shoulders of these giants, and we accept this prize with gratitude and renewed responsibility to push the science forward so that more people can return to full, meaningful lives after cardiac arrest.”

Pioneered and developed by an interdisciplinary and interprofessional group led by Prof. Dr. Georg Trummer and Prof. Dr. Christoph Benk, the CARL® platform embodies physiologically guided ECPR and is currently deployed across 12 European countries and select GCC countries in emergency rooms, cardiac units, ambulances, and rescue helicopters. Resuscitec is seeking FDA approval to bring CARL® to patients in the United States.

Beyond sudden cardiac arrest, Resuscitec is collaborating with Walter Reed National Military Medical Center to adapt CARL® for preservation of life, resuscitation, and reperfusion after massive blood loss. Additional applications are being explored in space medicine, oncology, and organ preservation for transplantation.

About Resuscitec
Resuscitec GmbH develops advanced technologies for resuscitation, organ and limb preservation, and circulatory support, with a mission to push the boundaries of life-saving care. The company’s CARL® ECPR system is designed to improve survival and neurological outcomes following sudden cardiac arrest.

About the Prix Galien USA
Established in France in 1970, the Prix Galien honors transformative advances in life sciences and medical technology. U.S. awardees are selected by a distinguished committee of leaders in science and medicine.

Media Contact
Angela Gorman, AMWPR
angela@amwpr.com

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)




Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets, the Company’s autologous gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The new J-code for ZEVASKYN, J3389 (Topical administration, prademagene zamikeracel, per treatment) becomes effective on January 1, 2026.

“The assignment of a unique, product-specific J-code by CMS is a major step forward in ZEVASKYN’s launch,” said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. “This code will simplify claims and reimbursement processing between our qualified treatment centers and payers across public and private sectors, and further support hospital adoption and patient access for ZEVASKYN.”

J-codes are unique identifiers designed to identify non-orally administered medications in healthcare settings. A J-code plays a vital role in streamlining the medical billing and reimbursement processes related to drug administration.

About ZEVASKYN^® (prademagene zamikeracel) gene-modified cellular sheets

ZEVASKYN is the first and only autologous cell sheet-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a severe skin disease caused by a defect in both copies of the COL7A1 gene, resulting in the inability to produce functional type VII collagen. Without functional type VII collagen and anchoring fibrils, the skin is fragile and blisters easily, leading to wounds that continually open and close, or fail to heal altogether. Patients often have large open wounds that can lead to serious life-threatening complications. ZEVASKYN gene modified cellular sheets are made by inserting the correct COL7A1 gene into a patient’s own skin cells ex vivo using a replication-incompetent retroviral vector, resulting in functional type VII collagen expression in treated wounds. ZEVASKYN has demonstrated clinically meaningful wound healing and pain reduction with a single surgical application. For more information, visit www.ZEVASKYN.com.

Indication

ZEVASKYN^® (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).

Important Safety Information

• Serious allergic reactions to ZEVASKYN can occur. Patients should get medical help right away if they experience symptoms like itching, swelling, hives, difficulty breathing, runny nose, watery eyes, or nausea. In rare cases, a severe reaction called anaphylaxis may happen.
• There is a potential risk that treatment with ZEVASKYN may contribute to the development of cancer because of how the therapy works. Patients should be monitored for the rest of their lives to check for any signs of cancer.
• ZEVASKYN is made using human and animal materials. Although these materials are tested before use, the risk of passing on infections cannot be eliminated.
• The most common side effects are pain from the procedure and itching.

This is not a complete list of side effects. Patients should call their care team for medical advice about side effects. Side effects may be reported to Abeona at 1-844-888-2236 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See full Prescribing Information.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN^® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.

ZEVASKYN^®, Abeona Assist™, Abeona Therapeutics^®, and their related logos are trademarks of Abeona Therapeutics Inc.

Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to commercialize ZEVASKYN; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

CONTACT: Contacts:

Investor and Media
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com

Investor
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com